# Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

> **NCT03813056** · PHASE2 · UNKNOWN · sponsor: **Michael D. Straiko, MD** · enrollment: 72 (estimated)

## Conditions studied

- Fuchs Endothelial Dystrophy

## Interventions

- **DRUG:** Glanatec
- **DRUG:** Optive, Ophthalmic Solution
- **PROCEDURE:** Descemet Membrane Endothelial Keratoplasty

## Key facts

- **NCT ID:** NCT03813056
- **Lead sponsor:** Michael D. Straiko, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-25
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813056, "Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03813056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*